Earlier and more aggressive treatment with biologics may prevent relapses and further new organ involvement in Behçet's disease
Authors:
- 14 February 2023
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 248, 109263
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Immunosuppressants reduce venous thrombosis relapse in Behçet's diseaseArthritis & Rheumatism, 2012
- Azathioprine in severe uveitis of Behçet's diseaseArthritis Care & Research, 2010
- Mortality in Behçet's diseaseArthritis & Rheumatism, 2010
- Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Behçet DiseaseAmerican Journal of Ophthalmology, 2008
- Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet's disease: An open‐label trialArthritis & Rheumatism, 2005
- The Long-Term Mortality and Morbidity of Behçet SyndromeMedicine, 2003
- Familial aggregation in Behçet’s disease: High frequency in siblings and parents of pediatric probandsThe Journal of Pediatrics, 1999
- Genetic anticipation in Behçet’s syndromeAnnals of the Rheumatic Diseases, 1998
- THE TEN-YEAR MORTALITY IN BEHÇET'S SYNDROMERheumatology, 1996
- Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome.Annals of the Rheumatic Diseases, 1984